Universal Corporation — FY2022 Form 10-K summary
Reporting period: The supplied filing is the annual report for the fiscal year ended March 31, 2022, filed May 27, 2022. This does not match the request metadata “2020 Q4”; the filing text does not provide a 2020 Q4 reporting period.
Business context
Universal is a global business-to-business supplier operating in more than 30 countries. Its two reportable segments are Tobacco Operations, its core leaf-tobacco sourcing and processing business, and Ingredients Operations, which supplies fruit- and vegetable-based ingredients, extracts, and flavorings. Tobacco accounted for 87% of FY2022 revenue and 90% of segment operating income. The company acquired botanical extracts and flavorings company Shank’s in October 2021 for approximately $100 million and continued integrating its acquired ingredients businesses.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $2,103.6 million | $1,983.4 million |
| Gross margin | 19.44% | 19.46% |
| Operating income | $160.3 million | $147.8 million |
| Net income attributable to Universal | $86.6 million | $87.4 million |
| Diluted EPS | $3.47 | $3.53 |
| Adjusted diluted EPS (non-GAAP) | $3.79 | $4.25 |
| Cash from operating activities | $44.9 million | $220.4 million |
- Revenue rose about 6%. Reported operating income increased 8%, but adjusted operating income was nearly flat at $173.6 million versus $172.9 million. Adjusted net income and adjusted EPS declined.
- Tobacco segment revenue was $1,835.8 million, nearly flat, while segment operating income decreased to $157.8 million from $168.8 million. Ingredients revenue increased 89% to $267.8 million and segment operating income rose to $16.6 million from $0.4 million; acquisitions contributed substantially to this growth.
- Operating cash flow fell by $175.5 million, mainly because of higher working-capital needs. Capital expenditures were $53.2 million. Cash and cash equivalents were $81.6 million at year-end, down from $197.2 million.
- Working capital was $1.229 billion and the current ratio was 3.37, compared with 5.31 a year earlier. Tobacco inventory increased to $822.5 million, largely due to shipment delays, higher green-leaf prices, and earlier Brazilian crop purchases.
- Long-term debt was $518.5 million; notes payable and overdrafts were $182.6 million. Management reported net debt of $633.3 million, up $202.3 million, and net debt to net capitalization of approximately 32%, versus 25%. The company said it complied with debt covenants and had no long-term debt maturing until FY2024.
- Common dividends were $3.12 per share for FY2022. The company repurchased 58,264 shares for $3.1 million and had approximately $97 million remaining under its repurchase authorization at year-end.
Material changes, outlook, and risks
- Shipping and container constraints delayed tobacco deliveries. Management estimated that about $70 million of tobacco revenue that otherwise might have shipped in FY2022 was deferred. Lower African burley crops also reduced tobacco volumes.
- Volatile Brazilian currency and tobacco markets drove unusually high green-leaf purchase prices and larger inventory write-downs. Inventory write-downs were $19.9 million, up from $13.5 million.
- FY2022 included $10.5 million of restructuring and impairment costs, chiefly a $9.4 million impairment related to idled Tanzania operations. A subsequent-event disclosure says the company agreed to sell the Tanzania tobacco companies for $8.5 million, subject to approvals and expected to close in FY2023.
- Management reported strong demand for tobacco and plant-based ingredients entering FY2023, and believed several tobacco types were in undersupply. It expected continued logistics constraints and higher freight, raw-material, labor, fertilizer, and energy costs, while stating confidence in delivering another good year. No specific FY2023 earnings or revenue guidance is provided. Planned FY2023 capital spending was $40–$50 million.
- Major risks include dependence on a small number of tobacco customers (the seven largest represented over 60% of consolidated revenue; three each exceeded 10% in FY2022), declining tobacco consumption, crop and weather variability, shipment timing, inflation, foreign-exchange movements, and pandemic or geopolitical disruption. Ingredients operations also face food safety, contamination, and concentrated sourcing or manufacturing risks.
- Brazil VAT assessments remain contested: the company disclosed possible losses of up to approximately $10 million and $3 million in two matters, respectively, but recorded no liability because management did not consider a loss probable. Other litigation was not expected to have a material effect, though outcomes remain uncertain.
- Other notable items include $2.5 million of income-tax benefits in FY2022 and the reversal of $2.5 million of FruitSmart contingent consideration, which affected reported results. Adjusted measures are non-GAAP and should be considered alongside GAAP results.
Important facts for investors to verify
- Confirm the intended period: this filing covers FY2022, not 2020 Q4.
- Track whether deferred tobacco shipments convert to revenue and whether freight and container availability improve.
- Assess inventory valuation, Brazilian crop purchase costs, and the level of uncommitted tobacco inventory, which was $130.1 million, or about 16% of tobacco inventory.
- Evaluate ingredients-segment growth and profitability apart from acquisition-related revenue, and the progress and costs of integrating Shank’s, Silva, and FruitSmart.
- Monitor cash conversion, seasonal borrowing, net debt, covenant headroom, and upcoming debt maturities.
- Review the resolution of the Tanzania sale and the contested Brazil VAT assessments, as well as customer concentration and changes in tobacco regulation or demand.